Lisanne de Koster, ETA 2021: FDG-PET/CT Prior to Diagnostic Thyroid Surgery

We caught up with Dr Lisanne de Koster, (Radboud University Medical Center, Nijmegen, The Netherlands) to discuss her study which investigated whether the use of FDG-PET/CT could prevent unnecessary diagnostic thyroid surgery.

The abstract ‘Efficacy of ¹⁸F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial’ (Abstract 49) was presented at the European Thyroid Association (ETA) Annual Meeting 2021, 4-7 September 2021.

Questions

1. How is papillary thyroid cancer currently diagnosed and prognosed? (0:15)
2. Why is it important to avoid unbeneficial diagnostic thyroid lobectomies and how might fludeoxyglucose (¹⁸F-FDG)-PET/CT imaging improve preoperative differentiation? (0:53)
3. What impact did FDG-PET/CT imaging have on unbeneficial diagnostic thyroid lobectomies? (2:36)
4. Are there any nodule types where FDG-PET/CT imaging was more or less useful in pre-operative nodule differentiation? (03:14)
5. What impact will these findings have on patients and is there anything more that needs to be done to inform clinical management guidelines (04:13)

Disclosures: Dr Lisanne de Koster has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.

Filmed in coverage of the European Thyroid Association (ETA) Annual Meeting 2021, 4-7 September 2021.

¹⁸F-FDG = 2-deoxy-2-[fluorine-18]fluoro-D-glucose; CT = computed tomography; PT = positron emission.

Reference

de Koster EJ, De Geus-Oei L-F, Brouwers AH, et al. 49: Efficacy of ¹⁸F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial. Eur Thyroid J 2021;10(Suppl. 1):13.